Senhwa Biosciences Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jason Huang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.6yrs |
| Board average tenure | 7.8yrs |
CEO
Jason Huang
less than a year
Tenure
Mr. Jason Huang, M.D. is Chief Medical Officer of Senhwa Biosciences, Inc. from June 3, 2024 and serves as its Acting Chief Executive Officer from 1st January 2025 and served as its Vice President since Au...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP | 11yrs | NT$8.76m | no data | |
| Acting CEO & Chief Medical Officer | less than a year | no data | no data | |
| Acting Chief Operating Officer & Business Development Director | 2.1yrs | no data | no data | |
| Director of Regulatory & Legal Affairs | 1.2yrs | no data | no data |
1.6yrs
Average Tenure
Experienced Management: 6492's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 12.3yrs | no data | 2.04% NT$ 77.1m | |
| Supervisor | 10yrs | no data | no data | |
| Director | 2.2yrs | no data | no data | |
| Supervisor | 8.8yrs | no data | no data | |
| Director | 7.8yrs | no data | no data | |
| Independent Director | 10yrs | NT$160.00k | no data | |
| Supervisor | 7.8yrs | no data | no data | |
| Independent Director | 4.8yrs | NT$80.00k | no data | |
| Independent Director | 4.8yrs | NT$80.00k | no data | |
| Director | less than a year | no data | no data |
7.8yrs
Average Tenure
Experienced Board: 6492's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/20 12:22 |
| End of Day Share Price | 2025/03/20 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Senhwa Biosciences, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Jane Jiang | Yuanta Research |